Enzymic Control of the Expression of the X Determinant (CD15) in Human Myeloid Cells During Maturation: the Regulatory Role of 6-sialytransferase
Overview
Authors
Affiliations
To establish the basis for the reduced expression of the X determinant on leukemic blasts and the changes in antigenic expression that occur during myeloid maturation, the presence on myeloid cells of X and related structures was examined in conjunction with studies on the activities of the glycosyltransferases involved in their biosynthesis. Expression of X and sialyl-X was weak on blasts in comparison with neutrophils despite the presence of the requisite precursor structures. Much higher levels of 3-fucosyltransferase activity were found in blasts than in neutrophils when nonsialylated substrates were used, but, whereas the enzyme in neutrophils reacted equally well with 3'-sialylated and nonsialylated acceptors, the enzyme in blasts showed a marked preference for nonsialylated substrates. 6'-Sialyltransferase activity was strong in blasts but was not detectable in neutrophils, whereas a much lower level of 3'-sialyltransferase activity was present in both blasts and neutrophils. Dimethyl sulfoxide-induced maturation of HL60 cells was associated with (1) a decrease in both 6'-sialyltransferase and 3-fucosyltransferase activities, (2) a change in the substrate specificity of 3-fucosyltransferase towards that found in mature cells, and (3) increased cell surface expression of sialyl-X. These results suggest that the reduced expression of X in myeloblasts is related to the presence of the strong 6'-sialyltransferase, which uses the precursor substrate at the expense of the 3-fucosyltransferase and prevents the synthesis of X and sialyl-X. The developmental regulation of the levels of 3'- and 6'-sialyltransferases, and the level and specificity of the 3-fucosyltransferases, therefore controls the expression of X and its degree of sialylation.
CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.
Stenzel P, Schindeldecker M, Seidmann L, Herpel E, Hohenfellner M, Hatiboglu G Pathobiology. 2023; 91(3):219-229.
PMID: 37963432 PMC: 11151972. DOI: 10.1159/000535201.
An S, Kim K, Lee Y, Kim S Genes Genomics. 2023; 45(7):901-909.
PMID: 37231294 DOI: 10.1007/s13258-023-01398-2.
High-Mannose -Glycans as Malignant Progression Markers in Early-Stage Colorectal Cancer.
Boyaval F, Dalebout H, Van Zeijl R, Wang W, Farina-Sarasqueta A, Lageveen-Kammeijer G Cancers (Basel). 2022; 14(6).
PMID: 35326703 PMC: 8945895. DOI: 10.3390/cancers14061552.
Regulation of ST6GAL1 sialyltransferase expression in cancer cells.
Dorsett K, Marciel M, Hwang J, Ankenbauer K, Bhalerao N, Bellis S Glycobiology. 2020; 31(5):530-539.
PMID: 33320246 PMC: 8176773. DOI: 10.1093/glycob/cwaa110.
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.
Rodrigues E, Macauley M Cancers (Basel). 2018; 10(6).
PMID: 29912148 PMC: 6025361. DOI: 10.3390/cancers10060207.